[{"id":"875719c8-7afc-4fa6-bbc9-fd581948c1ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02029729","created_at":"2021-01-18T09:18:16.136Z","updated_at":"2024-07-02T16:35:21.041Z","phase":"Phase 1","brief_title":"RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC \u0026 Melanoma) - DISCOVER","source_id_and_acronym":"NCT02029729","lead_sponsor":"Reata, a wholly owned subsidiary of Biogen","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Skyclarys (omaveloxolone)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 12/31/2013","start_date":" 12/31/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2024-02-02"},{"id":"1fd7db54-93ac-41e4-bc56-3603227c89e8","acronym":"ROCKET","url":"https://clinicaltrials.gov/study/NCT02096354","created_at":"2021-01-18T09:40:38.201Z","updated_at":"2024-07-02T16:36:10.444Z","phase":"Phase 2","brief_title":"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02096354 - ROCKET","lead_sponsor":"EpicentRx, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • irinotecan • nibrozetone (RRx-001)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/13/2018","primary_completion_date":" 04/13/2018","study_txt":" Completion: 04/13/2018","study_completion_date":" 04/13/2018","last_update_posted":"2022-05-16"}]